4.2 Editorial Material

Metformin: diamonds are forever

期刊

EXPERT OPINION ON PHARMACOTHERAPY
卷 10, 期 15, 页码 2395-2397

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560903176453

关键词

cardiovascular disease; diabetes mellitus; metformin; oral hypoglycaemic agents

向作者/读者索取更多资源

Metformin has now been established as the drug of choice for the first-line management of type 2 diabetes mellitus. It reduces insulin resistance, improves glycaemic control, and can be safely combined with other classes of oral hypoglycaemic agents. Equally important, metformin has been shown to have a significant beneficial effect on cardiovascular morbidity. Moreover, this agent acts favourably on blood pressure, lipids, haemostasis and other features of the metabolic syndrome. Metformin also contributes to weight reduction and diabetes prevention.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据